The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
CHICAGO, Oct. 25, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Eaton Corporation (NYSE:ETN-Free Report), Baxter International Inc. (NYSE:BAX-Free Report), Bio-Rad Laboratories, Inc. (NYSE:BIO-Free Report), INSYS Therapeutics, Inc. (Nasdaq:INSY-Free Report), and Boston Scientific Corp. (NYSE:BSX-Free Report).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday's Analyst Blog:
Can Eaton (ETN) Beat Earnings?
We expect diversified power management company Eaton Corporation (NYSE:ETN-Free Report) to beat expectations when it reports third quarter 2013 results before the market opens on Oct 25.
The company had missed the earnings consensus in the second quarter by 1.80%.
Why a Likely Positive Surprise?
Our proven model shows that Eaton is likely to beat earnings because it has the right combination of two key ingredients.
Positive Zacks ESP: Expected Surprise Prediction or Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is at +2.68%. This is a meaningful and leading indicator of a likely positive earnings surprise for the shares.
Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks of #1, #2 and #3 have a significantly higher chance of beating earnings. The Sell-rated stocks (#4 and #5) should never be considered going into an earnings announcement.
The combination of Eaton Corporation's Zacks Rank #3 (Hold) and +2.68% ESP makes us confident of an earnings beat this quarter.
What is Driving the Better-than-Expected Earnings?
Eaton's presence in over 175 countries across the globe diversifies any region-specific risk with ample options to make up for any revenue shortfall in any particular region or market.
Consistent investment in Research & Development helps the company to improve the quality of its product offering and improvise new products. This expands the company's operations and customer base.
In addition, solid performance from the acquired assets is helping the company to post better numbers. We expect this trend to continue this quarter.
Baxter Intros HEMOSTAT to Europe
Baxter International Inc. (NYSE:BAX-Free Report) declared the commercial launch of HEMOPATCH Sealing Hemostat, following CE mark approval in Europe. The development of this new collagen-based hemostatic device showcases the strong expertise of the company in collagen, internal coagulation processes and PEG (polyethylene glycol) technology platforms.
The HEMOPATCH is an important addition to Baxter's BioSurgery product portfolio, which consists of a range of biological and synthetic products and delivery devices used for hemostasis, tissue sealing, adhesion reduction, hard tissue regeneration, as well as soft tissue repair and microsurgery products.
Hemostasis is a physiological process which stops bleeding resulting from a cut or injury. Bleeding in surgical procedures is a major problem encountered by all surgeons. Complications from excessive bleeding may include blood loss, tissue damage, infection and excessive scarring. If uncontrolled, it can even turn out to be life-threatening.
Baxter's HEMOPATCH will provide a unique solution to this problem. It is a resorbable hemostatic device effectively designed to stop bleeding in surgical situations where other conventional methods often fail.
The thin, soft and flexible collagen pad allows surgeons to attain rapid hemostasis, as it firmly adheres to the bleeding tissue surface. Further, the specially-formulated porous collagen matrix, covered on one side with a thin protein bonding layer, known as NHS-PEG, helps to seal off the bleeding surface, initiating the body's own clotting process.
The new surgical tool promises to be a boon for surgeons. It is quick and effective, requires zero preparation time, and can be applied to varied surgical settings. Preclinical testing has also guaranteed the product's hemostatic performance, biocompatibility, and safety profile.
Baxter plans to launch the new bio surgical product in other countries as well.
Recently it launched HyQvia, a replacement therapy for adults with primary and secondary immunodeficiencies, in Germany. Additional product launches in the European markets are also on the cards.
Baxter currently carries a Zacks Rank #3 (Hold). Other stocks that are worth a look include Bio-Rad Laboratories, Inc. (NYSE:BIO-Free Report) and INSYS Therapeutics, Inc. (Nasdaq:INSY-Free Report), each carrying a Zacks Rank #1 (Strong Buy) and Boston Scientific Corp. (NYSE:BSX-Free Report) carrying a Zacks Rank #2 (Buy).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on ETN - FREE
Get the full Report on BAX - FREE
Get the full Report on BIO - FREE
Get the full Report on INSY - FREE
Get the full Report on BSX - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
SOURCE Zacks Investment Research, Inc.
Share this article